Our medical experts have created this comprehensive overview of maribavir in clearing CMV viraemia and improving symptom control in both solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients with refractory/resistant CMV infection/disease. Key highlights include:
- Efficacy: Maribavir significantly outperformed conventional antiviral therapies, achieving higher CMV clearance rates by Week 8.
- Safety: The SOLSTICE study revealed an improved safety profile for Maribavir, with fewer treatment-related adverse events compared to valganciclovir/ganciclovir and foscarnet.
- Patient Outcomes: Despite the more severe profiles of patients in the study, maribavir showed coherent effectiveness and safety findings, aligning with the pivotal study results.
C-ANPROM/BE/LIV/0014 July 2025